Philadelphia chromosome‐like B‐acute lymphoblastic leukemia and disseminated juvenile xanthogranulomatosis with shared KRAS mutation

Pediatric Blood & CancerEarly View e30963 LETTER TO THE EDITOR Philadelphia chromosome-like B-acute lymphoblastic leukemia and disseminated juvenile xanthogranulomatosis with shared KRAS mutation Jinjun Cheng, Corresponding Author Jinjun Cheng [email protected] orcid.org/0000-0001-8930-7903 Department of Pathology and Laboratory Medicine, Children's National Hospital, Washington, District of Columbia, USA Center for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA Correspondence Jinjun Cheng, Pathology and Laboratory Medicine Division, Children's National Hospital, Washington, DC 20010–2970, USA. Email: [email protected] Birte Wistinghausen, Center for Cancer and Blood Disorders, Children's National Hospital, 111 Michigan Ave NW, Washington, DC 20010, USA. Email: [email protected]Search for more papers by this authorNikolaos Svoronos, Nikolaos Svoronos Center for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA Center for Cancer and Blood Disorder, Children's National Hospital, Washington, District of Columbia, USASearch for more papers by this authorMiao Pan, Miao Pan Department of Pathology and Laboratory Medicine, Children's National Hospital, Washington, District of Columbia, USA George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USASearch for more papers by this authorShelby Smith, Shelby Smith Center for Cancer and Blood Disorder, Children's National Hospital, Washington, District of Columbia, USASearch for more papers by this authorAnant Vatsayan, Anant Vatsayan Center for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA Center for Cancer and Blood Disorder, Children's National Hospital, Washington, District of Columbia, USASearch for more papers by this authorDavid Jacobsohn, David Jacobsohn Center for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA Center for Cancer and Blood Disorder, Children's National Hospital, Washington, District of Columbia, USASearch for more papers by this authorBirte Wistinghausen, Corresponding Author Birte Wistinghausen [email protected] Center for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA Center for Cancer and Blood Disorder, Children's National Hospital, Washington, District of Columbia, USA Correspondence Jinjun Cheng, Pathology and Laboratory Medicine Division, Children's National Hospital, Washington, DC 20010–2970, USA. Email: [email protected] Birte Wistinghausen, Center for Cancer and Blood Disorders, Children's National Hospital, 111 Michigan Ave NW, Washington, DC 20010, USA. Email: [email protected]Search for more papers by this author Jinjun Cheng, Corresponding Author Jinjun Cheng [email protected] orcid.org/0000-0001-8930-7903 Department of Pathology and Laboratory Medicine, Children's National Hospital, Washington, District of Columbia, USA Center for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA Correspondence Jinjun Cheng, Pathology and Laboratory Medicine Division, Children's National Hospital, Washington, DC 20010–2970, USA. Email: [email protected] Birte Wistinghausen, Center for Cancer and Blood Disorders, Children's National Hospital, 111 Michigan Ave NW, Washington, DC 20010, USA. Email: [email protected]Search for more papers by this authorNikolaos Svoronos, Nikolaos Svoronos Center for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA Center for Cancer and Blood Disorder, Children's National Hospital, Washington, District of Columbia, USASearch for more papers by this authorMiao Pan, Miao Pan Department of Pathology and Laboratory Medicine, Children's National Hospital, Washington, District of Columbia, USA George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USASearch for more papers by this authorShelby Smith, Shelby Smith Center for Cancer and Blood Disorder, Children's National Hospital, Washington, District of Columbia, USASearch for more papers by this authorAnant Vatsayan, Anant Vatsayan Center for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA Center for Cancer and Blood Disorder, Children's National Hospital, Washington, District of Columbia, USASearch for more papers by this authorDavid Jacobsohn, David Jacobsohn Center for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA Center for Cancer and Blood Disorder, Children's National Hospital, Washington, District of Columbia, USASearch for more papers by this authorBirte Wistinghausen, Corresponding Author Birte Wistinghausen [email protected] Center for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA Center for Cancer and Blood Disorder, Children's National Hospital, Washington, District of Columbia, USA Correspondence Jinjun Cheng, Pathology and Laboratory Medicine Division, Children's National Hospital, Washington, DC 20010–2970, USA. Email: [email protected] Birte Wistinghausen, Center for Cancer and Blood Disorders, Children's National Hospital, 111 Michigan Ave NW, Washington, DC 20010, USA. Email: [email protected]Search for more papers by this author First published: 24 March 2024 https://doi.org/10.1002/pbc.30963 Jinjun Cheng and Nikolaos Svoronos contributed equally and share first authorship. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1Downing JR, Shannon KM. Acute leukemia: a pediatric perspective. Cancer Cell. 2002; 2(6): 437-445. 10.1016/S1535-6108(02)00211-8 CASPubMedWeb of Science®Google Scholar 2Harvey RC, Tasian SK. Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia. Blood Adv. 2020; 4(1): 218-228. 10.1182/bloodadvances.2019000163 CASPubMedWeb of Science®Google Scholar 3Roberts KG, Reshmi SC, Harvey RC, et al. Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group. Blood. 2018; 132(8): 815-824. 10.1182/blood-2018-04-841676 CASPubMedWeb of Science®Google Scholar 4Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014; 371(11): 1005-1015. 10.1056/NEJMoa1403088 CASPubMedWeb of Science®Google Scholar 5McClain KL, Bigenwald C, Collin M, et al. Histiocytic disorders. Nat Rev Dis Primers. 2021; 7(1): 73. 10.1038/s41572-021-00307-9 PubMedWeb of Science®Google Scholar 6Castro EC, Blazquez C, Boyd J, et al. Clinicopathologic features of histiocytic lesions following ALL, with a review of the literature. Pediatr Dev Pathol. 2010; 13(3): 225-237. 10.2350/09-03-0622-OA.1 PubMedWeb of Science®Google Scholar 7Fenu EM, Margolskee E, Pillai V. Transdifferentiation of B-lymphoblastic leukemia to histiocytic sarcoma after immunotherapy. Am J Hematol. 2023; 98(8): E216-E218. 10.1002/ajh.26983 CASPubMedWeb of Science®Google Scholar 8Kato M, Seki M, Yoshida K, et al. Genomic analysis of clonal origin of Langerhans cell histiocytosis following acute lymphoblastic leukaemia. Br J Haematol. 2016; 175(1): 169-172. 10.1111/bjh.13841 PubMedWeb of Science®Google Scholar 9Pawinska-Wa Sikowska K, Cwiklinska M, Wyrobek E, et al. Disseminated juvenile xanthogranuloma and hemophagocytic lymphohistiocytosis developed during treatment of acute lymphoblastic leukemia: case report. Front Oncol. 2020; 10: 921. 10.3389/fonc.2020.00921 PubMedWeb of Science®Google Scholar 10Feldman AL, Minniti C, Santi M, Downing JR, Raffeld M, Jaffe ES. Histiocytic sarcoma after acute lymphoblastic leukaemia: a common clonal origin. Lancet Oncol. 2004; 5(4): 248-250. 10.1016/S1470-2045(04)01428-7 PubMedWeb of Science®Google Scholar 11Newman H, MacFarland SP, Brodeur GM, et al. B-cell acute lymphoblastic leukemia and juvenile xanthogranuloma in a patient with ETV6 thrombocytopenia and leukemia predisposition syndrome: novel clinical presentation and perspective. Haematologica. 2023. doi:10.3324/haematol.2023.284151 10.3324/haematol.2023.284151 PubMedGoogle Scholar 12Salzer WL, Burke MJ, Devidas M, et al. Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: a report from the Children's Oncology Group study AALL1131. Cancer. 2018; 124(6): 1150-1159. 10.1002/cncr.31099 CASPubMedWeb of Science®Google Scholar 13Aparicio G, Mollet J, Bartralot R, et al. Eruptive juvenile xanthogranuloma associated with relapsing acute lymphoblastic leukemia. Pediatr Dermatol. 2008; 25(4): 487-488. 10.1111/j.1525-1470.2008.00721.x CASPubMedWeb of Science®Google Scholar 14Bailey KM, Castle VP, Hummel JM, Piert M, Moyer J, McAllister-Lucas LM. Thalidomide therapy for aggressive histiocytic lesions in the pediatric population. J Pediatr Hematol Oncol. 2012; 34(6): 480-483. 10.1097/MPH.0b013e3182580d6e CASPubMedWeb of Science®Google Scholar 15Cheon E, Yang S, Han JH, Lee KC, Park JE. Systemic juvenile xanthogranuloma involving the bone marrow, multiple bones, and the skin that developed during treatment of acute lymphoblastic leukemia in remission state. Pediatr Dev Pathol. 2018; 21(5): 489-493. 10.1177/1093526617721775 PubMedWeb of Science®Google Scholar 16Perez-Becker R, Szczepanowski M, Leuschner I, et al. An aggressive systemic juvenile xanthogranuloma clonally related to a preceding T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011; 56(5): 859-862. 10.1002/pbc.22756 PubMedWeb of Science®Google Scholar 17Rotte JJ, de Vaan GA, Koopman RJ. Juvenile xanthogranuloma and acute leukemia: a case report. Med Pediatr Oncol. 1994; 23(1): 57-59. 10.1002/mpo.2950230110 CASPubMedWeb of Science®Google Scholar 18Morier P, Merot Y, Paccaud D, Beck D, Frenk E. Juvenile chronic granulocytic leukemia, juvenile xanthogranulomas, and neurofibromatosis. Case report and review of the literature. J Am Acad Dermatol. 1990; 22(5): 962-965. 10.1016/0190-9622(90)70136-6 CASPubMedWeb of Science®Google Scholar 19Paxton CN, O'Malley DP, Bellizzi AM, et al. Genetic evaluation of juvenile xanthogranuloma: genomic abnormalities are uncommon in solitary lesions, advanced cases may show more complexity. Mod Pathol. 2017; 30(9): 1234-1240. 10.1038/modpathol.2017.50 CASPubMedWeb of Science®Google Scholar 20Egan C, Lack J, Skarshaug S, et al. The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy. Mod Pathol. 2021; 34(2): 336-347. 10.1038/s41379-020-00673-x CASPubMedWeb of Science®Google Scholar 21Irving J, Matheson E, Minto L, et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood. 2014; 124(23): 3420-3430. 10.1182/blood-2014-04-531871 CASPubMedWeb of Science®Google Scholar 22Feldman AL, Berthold F, Arceci RJ, et al. Clonal relationship between precursor T-lymphoblastic leukaemia/lymphoma and Langerhans-cell histiocytosis. Lancet Oncol. 2005; 6(6): 435-437. 10.1016/S1470-2045(05)70211-4 PubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issuee30963 ReferencesRelatedInformation